The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb

Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib

(2021) Masamitsu Mikami et al.   PEDIATRICS INTERNATIONAL

Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor

(2020) Saskia B Wortmann et al.   BLOOD

A lipidome atlas in MS-DIAL 4

(2020) Hiroshi Tsugawa et al.   NATURE BIOTECHNOLOGY

Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib

(2020) Sarah C. Grünert et al.   Orphanet Journal of Rare Diseases

Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency

(2019) Maria Veiga-da-Cunha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development and characterization of an inducible mouse model for glycogen storage disease type Ib

(2018) Federica Raggi et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Model analysis of effect of canagliflozin (Invokana), a sodium–glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol

(2016) Danielle Fortuna et al.   CLINICA CHIMICA ACTA

The Perseus computational platform for comprehensive analysis of (prote)omics data

(2016) Stefka Tyanova et al.   NATURE METHODS

Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes

(2014) Janice Y. Chou et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

(2013) R. A. DeFronzo et al.   DIABETES CARE

High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation

(2013) Manjunath B. Joshi et al.   FEBS LETTERS